DE · 5EA.DE
Elanco Animal Health Inc
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Greenfield, IN
- Website
- elanco.com
Price · as of 2025-12-31
$19.00
Market cap 11.28B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.80 | +25.24% |
| Intrinsic Value(DCF) | $8.82 | -53.59% |
| Graham-Dodd Method(GD) | $1.00 | -94.74% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $7.80 | $0.00 | |||
| 2018 | $7.30 | $3.30 | |||
| 2019 | $0.00 | $1.30 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $1.60 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $5.80 | $4.90 | |||
| 2025 | $22.05 | $27.83 | $0.00 | $1.00 | $0.00 |
AI valuation
Our deep-learning model estimates Elanco Animal Health Inc's (5EA.DE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.80
- Current price
- $19.00
- AI upside
- +25.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.82
-53.59% upside
Graham-Dodd
$1.00
-94.74% upside
Graham Formula
—
— upside
About Elanco Animal Health Inc
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. The company is headquartered in Greenfield, Indiana and currently employs 5,590 full-time employees. The firm offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The company provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The company also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The company also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. The company also provides products in poultry and aquaculture production.
- CEO
- Jeffrey N. Simmons
- Employees
- 5.76K
- Beta
- 1.86
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.82 ÷ $19.00) − 1 = -53.59% (DCF, example).